新型环状RNA调控胶质瘤化疗耐药的最新进展

Recent progress of novel circular RNA regulating chemotherapy resistance in glioma

胶质瘤是一种复发率极高的恶性肿瘤。临床上伴随着化疗药物使用时间的延长,胶质瘤细胞对化疗药物的耐药性也在不断增强,最终导致患者预后不良以及总体生存时间缩短。肿瘤细胞耐药机制复杂,包括药物转运代谢、细胞凋亡、DNA损伤修复、自噬、肿瘤干细胞变异、上皮间充质转化等。环状RNA(circRNA)是一种具有独特稳定性和组织特异性的新型RNA分子。越来越多的证据表明,大量异常表达的circRNA在胶质瘤化疗耐药中发挥核心作用,其可以靶向调节化疗敏感性。本文系统地综述了胶质瘤的多种耐药机制,并重点讨论了circRNA在胶质瘤替莫唑胺耐药调控中的作用及分子机制,同时对circRNA作为新型治疗靶点的潜在功能进行展望,旨在为开发新的治疗方法提供理论依据。

Glioma is a malignant tumor with extremely high rates of recurrence.Clinically,with the prolongation of the use of chemotherapy drugs,the drug resistance of glioma cells to chemotherapy drugs is also increasing,which eventually leads to poor prognosis and shortens overall survival time of patients.It is well known that the development of drug resistance involves multiple mechanisms,including drug transport metabolism,apoptosis,DNA damage repair,autophagy,variation of cancer stem cells and epithelial mesenchymal transition.Abnormal expression of circular RNA(circRNA),a novel RNA molecule with unique stability and tissue specificity,has been shown by more and more evidence to play a crucial regulatory role in the development of drug resistance in glioma.This paper systematically reviews the mechanism of multiple drug resistance in glioma,and focuses on the role and molecular mechanism of circRNA regulating temozolomide-resistance in glioma.At the same time,the potential function of circRNA as a new therapeutic target is prospected,in order to provide an objective theoretical basis for the development of new therapeutic methods.